Literature DB >> 28127860

Investigation of the bindings of a class of inhibitors with GSK3β kinase using thermodynamic integration MD simulation and kinase assay.

Chia-Jen Hsu1, Wen-Chi Hsu1, Der-Jay Lee1, An-Lun Liu1, Chia-Ming Chang1, Huei-Jhen Shih1, Wun-Han Huang2, Guey-Jen Lee-Chen2, Hsiu Mei Hsieh-Li2, Guan-Chiun Lee2, Ying-Chieh Sun1.   

Abstract

GSK3β kinase is a noteworthy target for discovery of the drugs that will be used to treat several diseases. In the effort to identify a new inhibitor lead compound, we utilized thermodynamic integration (TI)-molecular dynamics (MD) simulation and kinase assay to investigate the bindings between GSK3β kinase and five compounds that were analogous to a known inhibitor with an available crystal structure. TI-MD simulations of the first two compounds (analogs 1 and 2) were used for calibration. The computed binding affinities of analogs 1 and 2 agreed well with the experimental results. The rest three compounds (analogs 3-5) were newly obtained from a database search, and their affinity data were newly measured in our labs. TI-MD simulations predicted the binding modes and the computed ΔΔG values have a reasonably good correlation with the experimental affinity data. These newly identified inhibitors appear to be new leads according to our survey of GSK3β inhibitors listed in recent review articles. The predicted binding modes of these compounds should aid in designing new derivatives of these compounds in the future.
© 2017 John Wiley & Sons A/S.

Entities:  

Keywords:  GSK3β kinase; MD simulation; enzyme assay; inhibitor; thermodynamic integration

Mesh:

Substances:

Year:  2017        PMID: 28127860     DOI: 10.1111/cbdd.12946

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  1 in total

1.  A computational study on the interactions between a layered imine-based COF structure and selected anticancer drugs.

Authors:  Rahim Ghadari; Sevda Ghanbari; Yousef Mohammadzadeh
Journal:  J Mol Model       Date:  2021-01-20       Impact factor: 1.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.